Similar articles

• Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.

  Devereux RB, Dahlöf B. Devereux RB, et al. Curr Med Res Opin. 2007 Feb;23(2):443-57. doi: 10.1185/030079906X167435. Curr Med Res Opin. 2007. PMID: 17288698 Review.
• Hypertension to heart failure: a pathophysiological spectrum relating blood pressure, drug treatments and stroke.

  Subramaniam V, Lip GY. Subramaniam V, et al. Expert Rev Cardiovasc Ther. 2009 Jun;7(6):703-13. doi: 10.1586/erc.09.43. Expert Rev Cardiovasc Ther. 2009. PMID: 19505285
• [Significance of left ventricular hypertrophy in primary hypertension and therapeutic modification by antihypertensive drugs].

  Schiemann AL, Stimpel M. Schiemann AL, et al. Praxis (Bern 1994). 1997 Jul 2;86(27-28):1101-6. Praxis (Bern 1994). 1997. PMID: 9324718 Review. German.
• Prevalence of paroxysmal atrial fibrillation depending on the regression of left ventricular hypertrophy in arterial hypertension.

  Hennersdorf MG, Schueller PO, Steiner S, Strauer BE. Hennersdorf MG, et al. Hypertens Res. 2007 Jun;30(6):535-40. doi: 10.1291/hypres.30.535. Hypertens Res. 2007. PMID: 17664857
• Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.

  Li Z, Dahlöf B, Okin PM, Kjeldsen SE, Wachtell K, Ibsen H, Nieminen MS, Jern S, Devereux RB. Li Z, et al. J Hypertens. 2008 Jun;26(6):1244-9. doi: 10.1097/HJH.0b013e3282fcc23c. J Hypertens. 2008. PMID: 18475164 Clinical Trial.